A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease

Models, Molecular 0301 basic medicine 570 Tumor Molecular Structure Pyridines 610 Molecular Cyclin-Dependent Kinase 8 Article Cyclin-Dependent Kinases Cell Line 3. Good health 03 medical and health sciences Models Cell Line, Tumor Molecular Probes Colonic Neoplasms Humans Spiro Compounds Protein Kinase Inhibitors
DOI: 10.1038/nchembio.1952 Publication Date: 2015-10-26T15:23:46Z
ABSTRACT
There is unmet need for chemical tools to explore the role of the Mediator complex in human pathologies ranging from cancer to cardiovascular disease. Here we determine that CCT251545, a small-molecule inhibitor of the WNT pathway discovered through cell-based screening, is a potent and selective chemical probe for the human Mediator complex-associated protein kinases CDK8 and CDK19 with >100-fold selectivity over 291 other kinases. X-ray crystallography demonstrates a type 1 binding mode involving insertion of the CDK8 C terminus into the ligand binding site. In contrast to type II inhibitors of CDK8 and CDK19, CCT251545 displays potent cell-based activity. We show that CCT251545 and close analogs alter WNT pathway-regulated gene expression and other on-target effects of modulating CDK8 and CDK19, including expression of genes regulated by STAT1. Consistent with this, we find that phosphorylation of STAT1(SER727) is a biomarker of CDK8 kinase activity in vitro and in vivo. Finally, we demonstrate in vivo activity of CCT251545 in WNT-dependent tumors.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (58)
CITATIONS (120)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....